Form D · Pharmaceuticals
Nacuity Pharmaceuticals, Inc.
Fort Worth, TX · CIK 0001690279
Offering snapshot reported Dec 30, 2025 · SEC filing
- Reported sold
- $8.39M Offering amount: $30M
- Investors reported
- 98 Form D · investor count
- Minimum accepted
- $9.38K Reported outside-investor minimum
- First sale
- Dec 11, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 30, 2025 | Initial | $8,393,350 | No comparison | 98 | SEC filing |
| Jan 3, 2022 | Amendment | $11,626,000 | $8,455,000vs Mar 30, 2021 | 144 | SEC filing |
| Mar 30, 2021 | Initial | $3,171,000 | No comparison | 71 | SEC filing |
| Jul 20, 2017 | Amendment | $9,227,000 | $1,917,000vs Jun 27, 2017 | 125 | SEC filing |
| Jun 27, 2017 | Initial | $7,310,000 | No comparison | 102 | SEC filing |
| Dec 8, 2016 | Initial | $1,973,000 | No comparison | 46 | SEC filing |
Offering details
- Securities
- Equity, Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $839K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-568281
Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant Conversion
The figure represents the fee on amount sold to date and that Maxim will also receive placement agent warrants.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLC | 120708 |
Source: Form D, filed Dec 30, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Isaac Blech | Director |
| Gerald Cagle | Director |
| Dr. Gerald D. Cagle | Director |
| Richard Chin, M.D. | Director |
| William Halden Conner | Director, Executive |
| Halden Conner | Director, Executive |
| Emmett Cunningham, Jr. | Director |
| Sanford J. Hillsberg | Director |
| Rusty Kelley | Director |
| Jami Kern | Executive |
| Charles Lieser | Executive |
| Robert Ruffolo | Director |
| Robin Steel | Director |
| Robin Steele | Director |
| Michael Wall | Executive |
| G. Michael Wall, Ph.D. | Executive |
| David Wohlberg | Director, Executive |
| Benjamin Yerxa | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Fort Worth Club Bldg. 306 W. 7 Th Street, Suite 310
Fort Worth, TX, 76102
Phone: 817-336-3000
Fort Worth, TX, 76102
Phone: 817-336-3000